Latest Investor Relations News

Orora Limited updates its Dividend Reinvestment Plan price for the upcoming ordinary dividend, maintaining a steady payout amid evolving shareholder options.

Arena REIT has declared a quarterly distribution of 4.8125 cents per security, aligning with its FY26 guidance, while activating a discounted Dividend Reinvestment Plan to encourage investor participation.

Coles Group Limited has updated its dividend details, confirming a fully franked 41 cent per share payout for the half-year ending January 2026, alongside a Dividend Reinvestment Plan price set at $21.32.

Global X Management (AUS) Limited has announced estimated distribution amounts for a suite of ASX-listed ETFs for the quarter ending 31 March 2026, alongside key dates for investors to note.

ActivEX Limited has raised nearly $400,000 through a strategic placement of shares at a slight premium, locking in investor support with a 12-month escrow. The funds aim to fuel ongoing exploration efforts and bolster working capital.

Commonwealth Bank of Australia has updated its 2026 interim dividend details, confirming a fully franked payout of AUD 2.35 per share and setting the Dividend Reinvestment Plan price at AUD 174.47 with no discount.

360 Capital FM Limited has activated the Distribution Reinvestment Plan (DRP) for 360 Capital REIT for the March 2026 quarter, offering securityholders a cost-effective way to reinvest distributions into additional securities.

Cochlear Limited has updated its dividend details, confirming a fully franked ordinary dividend of AUD 2.15 per share for the six months ending December 2025, payable in April 2026 across multiple currencies.

Atlas Arteria has announced an ordinary dividend of AUD 0.20 per security for the six months ending December 2025, payable in April 2026. The dividend is fully unfranked, reflecting foreign income components.

ADX Energy has responded to ASX inquiries about recent unusual trading activity, confirming no undisclosed information but highlighting a recent placement settlement as a possible factor.

EVE Health Group has increased its placement funding to $1.3 million, backed by a cornerstone investor with pharmaceutical expertise, advancing its reformulated drug programs targeting billion-dollar global markets.

Lachlan Star Limited has provided important clarifications on visible gold imagery from its New Waverley project, confirming high-grade assay results while cautioning on the qualitative nature of visual gold observations.